BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rognoni C, Ciani O, Sommariva S, Facciorusso A, Tarricone R, Bhoori S, Mazzaferro V. Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. Oncotarget. 2016;7:72343-72355. [PMID: 27579537 DOI: 10.18632/oncotarget.11644] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Chen X, Lai L, Ye J, Li L. Downstaging Therapies for Unresectable Hepatocellular Carcinoma Prior to Hepatic Resection: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:740762. [PMID: 34868936 DOI: 10.3389/fonc.2021.740762] [Reference Citation Analysis]
2 Rognoni C, Ciani O, Sommariva S, Tarricone R. Cost–effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma. Journal of Comparative Effectiveness Research 2018;7:209-21. [DOI: 10.2217/cer-2017-0050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
3 Facciorusso A. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art. World J Gastroenterol 2018; 24(2): 161-169 [PMID: 29375202 DOI: 10.3748/wjg.v24.i2.161] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 41] [Article Influence: 12.5] [Reference Citation Analysis]
4 Facciorusso A, Paolillo R, Tartaglia N, Ramai D, Mohan BP, Cotsoglou C, Chandan S, Ambrosi A, Bargellini I, Renzulli M, Sacco R. Efficacy of combined transarterial radioembolization and sorafenib in the treatment of hepatocarcinoma: A meta-analysis. Dig Liver Dis 2021:S1590-8658(21)00318-2. [PMID: 34193367 DOI: 10.1016/j.dld.2021.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Liu Q, Qian Y, Li P, Zhang S, Liu J, Sun X, Fulham M, Feng D, Huang G, Lu W, Song S. 131I-Labeled Copper Sulfide-Loaded Microspheres to Treat Hepatic Tumors via Hepatic Artery Embolization. Theranostics 2018;8:785-99. [PMID: 29344306 DOI: 10.7150/thno.21491] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
6 Wang W, Wang L, Xie X, Yan Y, Li Y, Lu Q. A gene-based risk score model for predicting recurrence-free survival in patients with hepatocellular carcinoma. BMC Cancer 2021;21:6. [PMID: 33402113 DOI: 10.1186/s12885-020-07692-6] [Reference Citation Analysis]
7 Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. J Hepatol 2017;67:173-83. [PMID: 28323121 DOI: 10.1016/j.jhep.2017.03.007] [Cited by in Crossref: 90] [Cited by in F6Publishing: 100] [Article Influence: 18.0] [Reference Citation Analysis]
8 Tong AK, Tham WY, Too CW, Tai DW, Chow PK, Ng DC. Molecular Imaging and Therapy of Liver Tumors. Semin Nucl Med 2020;50:419-33. [PMID: 32768006 DOI: 10.1053/j.semnuclmed.2020.04.004] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Jafargholi Rangraz E, Coudyzer W, Maleux G, Baete K, Deroose CM, Nuyts J. Multi-modal image analysis for semi-automatic segmentation of the total liver and liver arterial perfusion territories for radioembolization. EJNMMI Res 2019;9:19. [PMID: 30788640 DOI: 10.1186/s13550-019-0485-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
10 Floridi C, Pesapane F, Angileri SA, De Palma D, Fontana F, Caspani F, Barile A, Del Sole A, Masciocchi C, Lucignani G, Carrafiello G. Yttrium-90 radioembolization treatment for unresectable hepatocellular carcinoma: a single-centre prognostic factors analysis. Med Oncol 2017;34. [DOI: 10.1007/s12032-017-1021-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
11 Facciorusso A, Abd El Aziz MA, Singh S, Pusceddu S, Milione M, Giacomelli L, Sacco R. Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis. Cancers (Basel) 2020;12:E874. [PMID: 32260179 DOI: 10.3390/cancers12040874] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
12 Abdallah MA, Wongjarupong N, Hassan MA, Taha W, Abdalla A, Bampoh S, Onyirioha K, Nelson M, Glubranson LA, Wiseman GA, Fleming CJ, Andrews JC, Mahipal A, Roberts LR. The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study. Expert Rev Gastroenterol Hepatol 2020;14:619-29. [PMID: 32490691 DOI: 10.1080/17474124.2020.1777856] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Wallace MC, Samuelson S, Khoo T, Ooi J, Tibballs J, Ferguson J, Preen DB, Knuiman M, Garas G, MacQuillan G, Adams LA, Jeffrey GP. The MAAPE score in intermediate and advanced hepatocellular carcinoma treated with Yttrium-90 resin microsphere radioembolization. J Gastroenterol Hepatol 2020;35:1945-52. [PMID: 32036614 DOI: 10.1111/jgh.15008] [Reference Citation Analysis]
14 Helmberger T, Golfieri R, Pech M, Pfammatter T, Arnold D, Cianni R, Maleux G, Munneke G, Pellerin O, Peynircioglu B, Sangro B, Schaefer N, de Jong N, Bilbao JI; On behalf of the CIRT Steering Committee., On behalf of the CIRT Principal Investigators. Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT). Cardiovasc Intervent Radiol 2021;44:21-35. [PMID: 32959085 DOI: 10.1007/s00270-020-02642-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
15 Facciorusso A, Abd El Aziz MA, Sacco R. Efficacy of Regorafenib in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis. Cancers (Basel). 2019;12. [PMID: 31877664 DOI: 10.3390/cancers12010036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
16 Rognoni C, Ciani O, Sommariva S, Bargellini I, Bhoori S, Cioni R, Facciorusso A, Golfieri R, Gramenzi A, Mazzaferro V, Mosconi C, Ponziani F, Sacco R, Trevisani F, Tarricone R. Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis. BMC Cancer. 2018;18:715. [PMID: 29976149 DOI: 10.1186/s12885-018-4636-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
17 Rognoni C, Ciani O, Sommariva S, Tarricone R. Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Value Health 2017;20:336-44. [PMID: 28292478 DOI: 10.1016/j.jval.2016.09.2397] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
18 Thayer D, Noda C, Charalel R, Mills A, Chang R, Tao Y, Akinwande O. Survival comparison of hepatocellular carcinoma patients treated with radioembolization versus nonoperative/interventional treatment. J Comp Eff Res 2018;7:343-56. [PMID: 29553286 DOI: 10.2217/cer-2017-0064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Sposito C, Mazzaferro V. The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future. Hepatobiliary Surg Nutr 2018;7:487-9. [PMID: 30652096 DOI: 10.21037/hbsn.2018.10.06] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
20 Arranja AG, Hennink WE, Chassagne C, Denkova AG, Nijsen JFW. Preparation and characterization of inorganic radioactive holmium-166 microspheres for internal radionuclide therapy. Mater Sci Eng C Mater Biol Appl 2020;106:110244. [PMID: 31753348 DOI: 10.1016/j.msec.2019.110244] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
21 Arranja AG, Hennink WE, Denkova AG, Hendrikx RWA, Nijsen JFW. Radioactive holmium phosphate microspheres for cancer treatment. Int J Pharm 2018;548:73-81. [PMID: 29913219 DOI: 10.1016/j.ijpharm.2018.06.036] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
22 Teng Y, Ding X, Li W, Sun W, Chen J. A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma. Technol Cancer Res Treat 2022;21:15330338221075174. [PMID: 35313780 DOI: 10.1177/15330338221075174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment. AJR Am J Roentgenol 2017;209:277-88. [PMID: 28463538 DOI: 10.2214/AJR.17.18264] [Cited by in Crossref: 39] [Cited by in F6Publishing: 15] [Article Influence: 7.8] [Reference Citation Analysis]
24 Facciorusso A, Bargellini I, Cela M, Cincione I, Sacco R. Comparison between Y90 Radioembolization Plus Sorafenib and Y90 Radioembolization alone in the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis. Cancers (Basel) 2020;12:E897. [PMID: 32272656 DOI: 10.3390/cancers12040897] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Nabrinsky E, James E. Highlighting Survival with Yttrium-90 Radioembolization Therapy in Unresectable Hepatocellular Carcinoma. Cureus 2020;12:e8163. [PMID: 32550079 DOI: 10.7759/cureus.8163] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Soydal C, Araz M, Nak D, Akkus P, Baltacioğlu MH, Bilgic S, Kucuk NO. Analysis of prognostic factors in patients receiving transarterial radioembolization for unresectable hepatocellular carcinoma. Nucl Med Commun 2020;41:73-7. [PMID: 31800509 DOI: 10.1097/MNM.0000000000001122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
27 Li G, Kang W, Jin M, Zhang L, Zheng J, Jia K, Ma J, Liu T, Dang X, Yan Z, Gao Z, Xu J. Synergism of wt-p53 and synthetic material in local nano-TAE gene therapy of hepatoma: comparison of four systems and the possible mechanism. BMC Cancer 2019;19:1126. [PMID: 31747895 DOI: 10.1186/s12885-019-6162-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Lucà MG, Nani R, Schranz M, De Giorgio M, Iegri C, Agazzi R, Sala F, Virotta G, Sarti D, Conte G, Pinelli D, Nicora C, Colledan M, Sironi S, Fagiuoli S. Treatment of hepatocellular carcinoma: a cost analysis of yttrium-90 transarterial radioembolization versus sorafenib. Future Oncology 2018;14:727-35. [DOI: 10.2217/fon-2017-0566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Zaidi A, Ahmed S, Ahmed S, Brunet B, Davies J, Doll C, Dueck DA, Gordon V, Hebbard P, Kim C, Le D, Lee-Ying R, Lim H, Liu D, McGhie JP, Mulder K, Park J, Renouf D, Schellenberg D, Wong RPW, Moser M. Report from the Western Canadian Gastrointestinal Cancer Consensus Conference Virtual Education Series-Transition from Local to System Therapy and Optimal Sequencing of Systemic Therapy for HCC. Curr Oncol 2021;28:4317-27. [PMID: 34898545 DOI: 10.3390/curroncol28060367] [Reference Citation Analysis]
30 Petrillo M, Patella F, Pesapane F, Suter MB, Ierardi AM, Angileri SA, Floridi C, de Filippo M, Carrafiello G. Hypoxia and tumor angiogenesis in the era of hepatocellular carcinoma transarterial loco-regional treatments. Future Oncology 2018;14:2957-67. [DOI: 10.2217/fon-2017-0739] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
31 Henry EC, Strugari M, Mawko G, Brewer K, Liu D, Gordon AC, Bryan JN, Maitz C, Abraham R, Kappadath SC, Syme A. Precision dosimetry in yttrium-90 radioembolization through CT imaging of radiopaque microspheres in a rabbit liver model. EJNMMI Phys 2022;9:21. [PMID: 35312882 DOI: 10.1186/s40658-022-00447-1] [Reference Citation Analysis]
32 Van Thai N, Thinh NT, Ky TD, Bang MH, Giang DT, Ha LN, Son MH, Tien DD, Lee HW. Efficacy and safety of selective internal radiation therapy with yttrium-90 for the treatment of unresectable hepatocellular carcinoma. BMC Gastroenterol 2021;21:216. [PMID: 33980171 DOI: 10.1186/s12876-021-01805-6] [Reference Citation Analysis]
33 Pandey U, Subramanian S, Shaikh S, Gamre N, Kumar S, Dash A. Synthesis and Preliminary Biological Evaluation of 177Lu-Labeled Polyhydroxamic Acid Microparticles Toward Therapy of Hepatocellular Carcinoma. Cancer Biother Radiopharm 2019;34:306-15. [PMID: 31188652 DOI: 10.1089/cbr.2018.2747] [Reference Citation Analysis]
34 Sposito C, Spreafico C, Mazzaferro V. Reply to: "Validation of response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion". J Hepatol 2018;69:260-1. [PMID: 29705239 DOI: 10.1016/j.jhep.2018.04.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]